Furthermore, the present invention relates to a composition, a method of binding a zwitterionic nanoparticle and the use of a zwitterionic nanoparticle.

Superparamagnetic nanoparticle-based analytical method comprising providing a sample having analytes in a sample matrix, providing a point of care chip having analytical regions, each of which is a stationary phase having at least one or more sections, labeling each of the analytes with a superparamagnetic nanoparticle and immobilizing the labeled analytes in the stationary phase, providing an analytical device having a means for exciting the superparamagnetic nanoparticles in vitro and a means for sensing, receiving, and transmitting response of the excited superparamagnetic nanoparticles, placing the chip in the analytical device and exciting the superparamagnetic nanoparticles in vitro, sensing, receiving, and transmitting the response of the superparamagnetic nanoparticles, and analyzing the response and determining characteristic of the analytes, wherein the response of the superparamagnetic nanoparticles comprises harmonics. The present invention also provides the hybrid point of care chip and analyzer to be used in the analytical method.

The present application discloses an electrochemiluminescence (ECL) immunosensor. The ECL immunosensor includes an electrode modified by a nanocomposite comprising a mixture of carbon nanochips (CNCs); iron oxide (Fe.sub.3O.sub.4); and nafion (NAF). The electrode is a screen-printed electrode which further is a carbon screen-printed electrode (SPE). The carbon screen-printed electrode (SPE) is a mesoporous carbon screen-printed electrode (SPE). Ru(bpy).sub.3Cl.sub.2.6H.sub.2O is a luminophore and TPrA is a coreactant of the luminophore.

The present invention provides a fluorescent silica-based nanoparticle that allows for precise detection, characterization, monitoring and treatment of a disease such as cancer. The nanoparticle has a range of diameters including between about 0.1 nm and about 100 nm, between about 0.5 nm and about 50 nm, between about 1 nm and about 25 nm, between about 1 nm and about 15 nm, or between about 1 nm and about 8 nm. The nanoparticle has a fluorescent compound positioned within the nanoparticle, and has greater brightness and fluorescent quantum yield than the free fluorescent compound. The nanoparticle also exhibits high biostability and biocompatibility. To facilitate efficient urinary excretion of the nanoparticle, it may be coated with an organic polymer, such as poly(ethylene glycol) (PEG). The small size of the nanoparticle, the silica base and the organic polymer coating minimizes the toxicity of the nanoparticle when administered in vivo. In order to target a specific cell type, the nanoparticle may further be conjugated to a ligand, which is capable of binding to a cellular component associated with the specific cell type, such as a tumor marker. In one embodiment, a therapeutic agent may be attached to the nanoparticle. To permit the nanoparticle to be detectable by not only optical fluorescence imaging, but also other imaging techniques, such as positron emission tomography (PET), single photon emission computed tomography (SPECT), computerized tomography (CT), bioluminescence imaging, and magnetic resonance imaging (MRI), radionuclides/radiometals or paramagnetic ions may be conjugated to the nanoparticle.

The present disclosure provides a system comprising a communication interface and computer for assigning a label to the biomolecule fingerprint, wherein the label corresponds to a biological state. The present disclosure also provides a sensor arrays for detecting biomolecules and methods of use. In some embodiments, the sensor arrays are capable of determining a disease state in a subject.

The purpose of the present invention is to provide: a method which is for assessing the differentiation state of cells and by which the differentiation state of a wide variety of cells can be assessed; and gelatin nanoparticles which can be used in said method. The purpose is achieved by a method for assessing the differentiation state of cells, the method comprising a step for observing the expression of pyruvate dehydrogenase kinase 1 (PDK1) or mRNA (Pdk1) encoding pyruvate dehydrogenase kinase 1 in cells. Said method can be carried out by using gelatin nanoparticles which are used for assessing the differentiation state of cells and carry a probe capable of detecting Pdk1 or PDK1.

Certain aspects of the present disclosure generally relate to systems and methods for determining viruses such as coronaviruses. For instance, some aspects are directed to systems and methods for determining viruses using a partitioning system. Within the partitioning system, free RNA or other nucleic acids may preferentially partition into one phase, while intact viruses may be present in the other phase or in both phases. Accordingly, in some cases, free RNA or other nucleic acids may be preferentially removed, e.g., as compared to intact RNA or other nucleic acids present within a virus. In some cases, the phase containing intact viruses can be determined to determine the infectiousness, e.g., of a sample arising from a subject. This may be useful, for example, for distinguishing subjects who are capable of spreading an infection from those who are not infectious.

Provided are: a composite of a silicate-based base material and a rare-earth compound, having high light-emitting intensity and capable of being used as light-emitting particles, light-emitting nanoparticle including the same, a cell detection method, a method for treating an animal, a medical device, and a method for producing the composite of a silicate-based base material and a rare-earth compound. This composite of a silicate-based base material and a rare-earth compound includes elemental silicon (Si) and elemental oxygen (O), the rare-earth compound comprising at least one selected from a chloride of a rare-earth element and a fluoride of a rare-earth element, the silicate-based base material having a solid .sup.29Si-NMR spectrum satisfying Q.sub.4/Q.sub.3 of 1.6 to 3.9 where Q.sub.4 represents a peak area derived from Si(OSi)4 and Q.sub.3 represents a peak area derived from HO—Si(OSi).sub.3.

A mobile phone-based dark field microscope (MDFM) apparatus suitable for quantifying nanoparticle signals is provided. The MDFM apparatus includes an electrically operated light source, a dark-field condenser, a slide housing configured to receive an analytical slide, and an adapter housing configured to receive an objective lens and receive a portable electronic communication device. The slide housing positions the analytical slide between the objective lens and the dark-field condenser. The adapter housing registers the objective lens with a camera lens of the portable electronic communication device. A method for performing a biological quantitative study using the dark-field microscope apparatus is further provided.

Disclosed herein are integrated photonics systems (3800) for biosensing including an interrogator photonic circuit (3802) and cartridge (3804) and methods using these systems. The cartridge (3804) comprises a sensor photonic integrated subcircuit. The cartridge (3804) is configured to receive a biological sample. The interrogator photonic circuit (3802) is optically coupled to the cartridge (3804) an comprises: (i) a light source (3806) configured to generate light; and (ii) one or more waveguides configured to carry the light, wherein the light is used to determine a characteristic of the biological sample in the cartridge (3804). A system can have an assembly of a plurality of modular photonic integrated subcircuits. Each subcircuit can be pre-fabricated and can be configured to transfer light to and receive light from another subcircuit based on the first functionality. An output port of a first subset of the subcircuits can be configured to be aligned with an input port of a second subset of the subcircuits. At least one subcircuit can be configured to be removed from the first integrated photonics assembly and connected to a second integrated photonics assembly having a second functionality. The first integrated photonics assembly can be different from the second integrated photonics assembly and the first functionality can be different from the second functionality.